Mga Batayang Estadistika
| LEI | 5299005HUB5IOJGO7S39 |
| CIK | 1521036 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Lantheus Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36 |
|
| August 6, 2025 |
Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update • Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 million • Announced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent |
|
| August 6, 2025 |
Ninth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan Exhibit 10.1 Ninth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan This Amendment (this “Amendment”) to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan, as in effect from time to time (the “Plan”), is dated as of April 28, 2025. WHEREAS, pursuant to Section 16.2 of the Plan, the Talent and Compensation Committee (the “Committee”) desires to amend Section 16.2 of the Plan to |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 LANTHEUS HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36569 35-2318913 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 6, 2025 |
Exhibit 99.2 Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resilience PDUFA date set for March 6, 2026 BEDFORD, Mass., August 6, 2025 – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused comp |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| July 22, 2025 |
Exhibit 99.1 Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D BEDFORD, Mass., July 22, 2025 – Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. (“Life Molecular”), a subsidiary of Life Healthcare Group Holding |
|
| May 30, 2025 |
Conflict Minerals Report for the reporting period January 1, 2024 through December 31, 2024. EX-1.01 Exhibit 1.01 Lantheus Holdings, Inc. Conflict Minerals Report For The Year Ended December 31, 2024 Lantheus Holdings, Inc. (together with its subsidiaries, the “Company” or “we”) is filing this Conflict Minerals Report for the 2024 calendar year (this “Report”) in accordance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Rule”). The R |
|
| May 30, 2025 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 201 Burlington Road, South Building Bedford, MA 01730 (A |
|
| May 7, 2025 |
Exhibit 10.1 EXECUTION COPY THIRD AMENDMENT TO LEASE THIS THIRDAMENDMENT TO LEASE (“Third Amendment”) dated as of February 14, 2025 (the “Effective Date”), is entered into by and between 201 BURLINGTON ROAD OWNER, LLC (“Landlord”) and LANTHEUS MEDICAL IMAGING, INC. (“Tenant”). BACKGROUND A.Landlord and Tenant are parties to a lease dated February 14, 2022 (the “Original Lease”) for premises consis |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| May 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2025 |
Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update •Worldwide revenue of $372.8 million in the first quarter 2025 •GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024 •Free cash flow totaled $98.8 million for the |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 5, 2025 |
Amended and Restated Bylaws of Lantheus Holdings, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LANTHEUS HOLDINGS, INC. (a Delaware corporation) As of December 27May 1, 20222025 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Lantheus Holdings, Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as properly may come before such meeting shall be |
|
| April 1, 2025 |
Lantheus Completes Acquisition of Evergreen Theragnostics Exhibit 99.1 Lantheus Completes Acquisition of Evergreen Theragnostics BEDFORD, Mass., April 1, 2025 – Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has completed its previously announced acquisition o |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| March 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| March 21, 2025 |
DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 26, 2025 |
Form of Indemnification Agreement Confidential Exhibit 10.35 INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (the “Agreement”) is made effective as of between Lantheus Holdings, Inc., a Delaware corporation (“Holdings”), and Lantheus Medical Imaging, Inc., a Delaware corporation and wholly-owned subsidiary of Holdings (each a “Company” and collectively, with Holdings, the “Companies”), and [ ] (“Indemnitee”). Capitalized |
|
| February 26, 2025 |
Nonqualified Deferred Compensation Plan THE NONQUALIFIED DEFERRED COMPENSATION PLAN PLAN DOCUMENT Classification: Customer Confidential THE NONQUALIFIED DEFERRED COMPENSATION PLAN Section 1. |
|
| February 26, 2025 |
Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance Exhibit 99.1 Lantheus Reports Fourth Quarter and Full Year 2024 Financial Performance •Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024 •Free cash flow was $141.4 million and $493.1 million for the fourth quarter and full year 2024 •GAAP fully diluted loss per share of $(0.17) and earnings per share of $4.36 for the fourth quarter and full year 2024 • |
|
| February 26, 2025 |
Amended and Restated Executive Compensation Clawback Policy Exhibit 97.1 Lantheus Holdings, Inc. Amended and Restated Executive Compensation Clawback Policy Lantheus Holdings, Inc. (the “Company”) hereby adopts this Amended and Restated Executive Compensation Clawback Policy (this “Policy”), effective as of October 2, 2023 (the “Effective Date”). Certain capitalized terms are defined in Section 4 below. 1.Introduction. This Policy is intended to provide fo |
|
| February 26, 2025 |
Subsidiaries of Lantheus Holdings, Inc. Exhibit 21.1 LANTHEUS HOLDINGS, INC. SUBSIDIARIES Subsidiary State or Other Jurisdiction of Organization Aphelion LLC Delaware Cerveau Technologies, Inc. Delaware Excelsior Life Sciences Ireland Limited Ireland EXINI Diagnostics AB Sweden Lantheus Alpha Therapy, LLC Delaware Lantheus EU Limited Ireland Lantheus Five, LLC Delaware Lantheus Medical Imaging, Inc. Delaware Lantheus MI Canada, Inc. Can |
|
| February 26, 2025 |
Second Amendment to Lease dated as of October 3, 2024 Exhibit 10.32 Execution copy SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (“Second Amendment”) dated as of October 3, 2024 (the “Effective Date”), is entered into by and between 201 BURLINGTON ROAD OWNER, LLC (“Landlord”) and LANTHEUS MEDICAL IMAGING, INC. (“Tenant”). BACKGROUND A.Landlord and Tenant are parties to a lease dated February 14, 2022 (the “Original Lease”) for premises con |
|
| February 26, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 26, 2025 |
Policy on Insider Trading and Communications with the Public Exhibit 19.1 LANTHEUS HOLDINGS, INC. Policy on Insider Trading and Communications with the Public This Policy on Insider Trading and Communications with the Public (this “Policy”) applies to: •the purchase or sale of securities in Lantheus Holdings, Inc. (referred to herein as “Lantheus” and the “Company”); •the communication of material nonpublic information about the Company to persons or entiti |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 |
|
| February 26, 2025 |
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted and replaced by [***], as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed. |
|
| February 26, 2025 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Lantheus Holdings, Inc.’s (the “Company”, “us”, “we”, or “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF CAPITAL STOCK T |
|
| February 5, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The un |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| January 30, 2025 |
Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member Exhibit 99.1 Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member BEDFORD, Mass., January 30, 2025 (GLOBE NEWSWIRE) – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morr |
|
| January 28, 2025 |
Exhibit 99.1 Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader Advances radiopharmaceutical leadership with addition of scalable manufacturing infrastructure and end-to-end clinical development capabilities Adds OCTEVYTM, a registrational-stage diagnostic asset, targeting neuroendocrine tumo |
|
| January 28, 2025 |
© 2025 Lantheus. All rights reserved. Lantheus to Acquire Evergreen Theragnostics Solidifies Capabilities as a Fully Integrated Radiopharmaceutical Company January 28, 2025 Exhibit 99.2 Acquisition Overview & Strategic Rationale Transaction Summary Manufacturing Capabilities, Pipeline and Development Platform Growth Strategy Q&A Agenda © 2025 Lantheus. All rights reserved. Safe Harbor Statements C |
|
| January 28, 2025 |
EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER by and among: LANTHEUS MEDICAL IMAGING, INC., as Parent; PROJECT HAZEL MERGER SUB, INC., as Merger Sub; EVERGREEN THERAGNOSTICS, INC., as the Company; and SHAREHOLDER REPRESENTATIVE SERVICES LLC, as the Securityholders’ Representative and for purposes of Section 11.2 only, LANTHEUS HOLDINGS, INC. Dated as of January 27, 2025 TABLE OF CONTENTS Page ARTICLE I |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| January 13, 2025 |
© 2025 Lantheus. All rights reserved. Lantheus to Acquire Life Molecular Imaging Accelerating Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market January 13, 2025 Exhibit 99.2 Acquisition Overview & Strategic Rationale Transaction Summary Commercial Infrastructure and R&D Capabilities Growth Strategy Q&A Agenda © 2025 Lantheus. All rights reserved. Safe Harbor Stateme |
|
| January 13, 2025 |
Exhibit 99.1 Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceut |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2025 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| December 23, 2024 |
Exhibit 10.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT THIS FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of December 19, 2024 (this “Amendment”), is entered into by and among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (the “Borrower”), LANTHEUS HOLDINGS, INC., a Delaware corporation (“Holdings”), the Lenders party hereto (the “Consenting Lenders” which shall, for the avoid |
|
| December 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 20, 2024 |
Lantheus Announces Share Repurchase Program Exhibit 99.1 Lantheus Announces Share Repurchase Program BEDFORD, Mass., November 20, 2024 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurch |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2024 |
ISR / Perspective Therapeutics Inc / Farallon Capital Partners, L.P. Passive Investment SC 13G 1 lnth13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Lantheus Holdings, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 46489V104 (Cusip Number) November 8, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| November 6, 2024 |
Lantheus Reports Third Quarter 2024 Financial Results Exhibit 99.1 Lantheus Reports Third Quarter 2024 Financial Results •Worldwide revenue of $378.7 million, an increase of 18.4% from third quarter 2023 •GAAP fully diluted earnings per share of $1.79, compared to $1.88 in the third quarter of 2023. Adjusted fully diluted earnings per share of $1.70 compared to $1.47 in the third quarter of 2023 •Company narrows full year 2024 revenue and fully dilut |
|
| November 6, 2024 |
Eighth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan Exhibit 10.1 Eighth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan This Amendment (this “Amendment”) to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan, as in effect from time to time (the “Plan”), is dated as of October 22, 2024. WHEREAS, pursuant to Section 3.2 of the Plan, the Talent and Compensation Committee (the “Committee”) has the authority to interpret the terms of |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commiss |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| September 5, 2024 |
Lantheus Appoints Julie Eastland as New Board Member Exhibit 99.1 Lantheus Appoints Julie Eastland as New Board Member BEDFORD, Mass., September 5, 2024 (GLOBE NEWSWIRE) – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnolo |
|
| August 21, 2024 |
As filed with the Securities and Exchange Commission on August 21, 2024 S-8 As filed with the Securities and Exchange Commission on August 21, 2024 Registration No. |
|
| August 21, 2024 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Lantheus Holdings, Inc. |
|
| July 31, 2024 |
Exhibit 10.2 Certain identified information has been omitted from this exhibit because it is (i) not material and (ii) of the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. Execution Version CONSULTING AGREEMENT This Consulting Agreement is made by and between Lantheus Medical Imaging, Inc. (together with its affiliates, the “Company” |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36 |
|
| July 31, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| July 31, 2024 |
Lantheus Reports Second Quarter 2024 Financial Results Exhibit 99.1 Lantheus Reports Second Quarter 2024 Financial Results Second Quarter 2024 •Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 •Completed three strategic transactions to expand innovative pipeline •GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.5 |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| June 27, 2024 |
Exhibit 99.1 Lantheus Acquires Global Rights to Life Molecular Imaging’s Novel Therapeutic and Diagnostic Pair Targeting GRPR for Prostate and Breast Cancers Deal Further Strengthens Lantheus’ Prostate Cancer Portfolio and Expands Pipeline to Include Breast Cancer BEDFORD, Mass., June 27, 2024 – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company co |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 31, 2024 |
Conflict Minerals Report for the reporting period January 1, 2023 through December 31, 2023. Exhibit 1.01 Lantheus Holdings, Inc. Conflict Minerals Report For The Year Ended December 31, 2023 Lantheus Holdings, Inc. (together with its subsidiaries, the “Company” or “we”) is filing this Conflict Minerals Report for the 2023 calendar year (this “Report”) in accordance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Rule”). The Rule impo |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 (State or other jurisdiction of incorporation or organization) (Commission File Number) 201 Burlington Road, South Building Bedford, MA 01730 (Address of principal executive offices) (Zip Code |
|
| May 15, 2024 |
Exhibit 99.1 Lantheus Announces Executive Appointments to Accelerate Innovation Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer BEDFORD, Mass., May 15, 2024 — Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver b |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 2, 2024 |
Lantheus Reports First Quarter 2024 Financial Results Exhibit 99.1 Lantheus Reports First Quarter 2024 Financial Results First Quarter 2024 •Worldwide revenue of $370.0 million, an increase of 23.0% from first quarter 2023 •GAAP fully diluted net income per share of $1.87, compared to GAAP fully diluted net loss per share of $0.04 in first quarter 2023. Adjusted fully diluted net income per share of $1.69 compared to adjusted fully diluted net income |
|
| May 2, 2024 |
Exhibit 10.1 FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT (PNT-2002) This First Amendment to License and Collaboration Agreement (this “Amendment”) is entered into as of January 31, 2024, by and between POINT Biopharma, Inc., a Delaware corporation (“POINT”), and Lantheus Two, LLC, a Delaware limited liability company (“Lantheus”) and Lantheus Medical Imaging, Inc., a Delaware corporatio |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2024 |
Seventh Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan Exhibit 10.1 Seventh Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan This Amendment (this “Amendment”) to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan, as in effect from time to time (the “Plan”), is dated as of April 25, 2024. WHEREAS, pursuant to Section 16.2 of the Plan, the Compensation Committee desires to amend Section 4.1 of the Plan to increase the maximum number |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, f |
|
| March 8, 2024 |
CATX / Perspective Therapeutics, Inc. / Lantheus Holdings, Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 46489V104 (CUSIP Number) Lantheus Holdings, Inc. 201 Burlington Road, South Building Bedford, MA 01730 Attention: Daniel Niedzwiecki (97 |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 22, 2024 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Lantheus Holdings, Inc.’s (the “Company”, “us”, “we”, or “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF CAPITAL STOCK T |
|
| February 22, 2024 |
Amended and Restated Executive Compensation Clawback Policy Exhibit 97.1 Lantheus Holdings, Inc. Amended and Restated Executive Compensation Clawback Policy Lantheus Holdings, Inc. (the “Company”) hereby adopts this Amended and Restated Executive Compensation Clawback Policy (this “Policy”), effective as of October 2, 2023 (the “Effective Date”). Certain capitalized terms are defined in Section 4 below. 1.Introduction. This Policy is intended to provide fo |
|
| February 22, 2024 |
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results •Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023 •GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023 •GAAP fully diluted net income per share of $1.47 and $4.65 for the fourth quarter and full year 2023 •Adjusted fully diluted |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 |
|
| February 22, 2024 |
Subsidiaries of Lantheus Holdings, Inc. Exhibit 21.1 LANTHEUS HOLDINGS, INC. SUBSIDIARIES Subsidiary State or Other Jurisdiction of Organization Lantheus Medical Imaging, Inc. Delaware Lantheus MI Canada, Inc. Canada Lantheus MI Real Estate, LLC Delaware Lantheus MI UK Limited England and Wales Lantheus EU Limited Ireland Lantheus Two, LLC Delaware Lantheus Three, LLC Delaware Progenics Pharmaceuticals, Inc. Delaware Molecular Insight P |
|
| February 22, 2024 |
Policy on Insider Trading and Communications with the Public Exhibit 19.1 LANTHEUS HOLDINGS, INC. Policy on Insider Trading and Communications with the Public This Policy on Insider Trading and Communications with the Public (this “Policy”) applies to: •the purchase or sale of securities in Lantheus Holdings, Inc. (referred to herein as “Lantheus” and the “Company”); •the communication of material nonpublic information about the Company to persons or entiti |
|
| February 13, 2024 |
LNTH / Lantheus Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Lantheus Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 516544103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| February 1, 2024 |
EX-99.4 2 d785059dex994.htm EX-99.4 Exhibit 99.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 22, 2024, between Perspective Therapeutics, Inc., a Delaware corporation (the “Company”), and Lantheus Alpha Therapy, LLC, a Delaware limited liability company (the “Investor”). RECITALS This Agreement is made pursuant to the In |
|
| February 1, 2024 |
Power of Attorney (Lantheus Holdings, Inc.) EX-99.5 3 d785059dex995.htm EX-99.5 Exhibit 99.5 POWER OF ATTORNEY Know all by these presents, that Lantheus Holdings, Inc. (the “Company”) hereby constitutes and appoints each of Dan Niedzwiecki, Eric Green and Dustin Hawks of the Company and Jill Simon of Cooley LLP, signing singly, and with full power of substitution, the Company’s true and lawful attorneys-in-fact and agents to: (1) prepare, e |
|
| February 1, 2024 |
Power of Attorney (Lantheus Alpha Therapy, LLC) EX-99.6 4 d785059dex996.htm EX-99.6 EXHIBIT 99.6 POWER OF ATTORNEY Know all by these presents, that Lantheus Alpha Therapy, LLC (the “Company”) hereby constitutes and appoints each of Dan Niedzwiecki, Eric Green and Dustin Hawks of the Company and Jill Simon of Cooley LLP, signing singly, and with full power of substitution, the Company’s true and lawful attorneys-in-fact and agents to: (1) prepar |
|
| February 1, 2024 |
CATX / Perspective Therapeutics, Inc. / Lantheus Holdings, Inc. - SC 13D Activist Investment SC 13D 1 d785059dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Perspective Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 46489V104 (CUSIP Number) Lantheus Holdings, Inc. 201 Burlington Road, South Building Bedford, MA 01730 Attention: Daniel Niedzwie |
|
| February 1, 2024 |
EX-99.7 5 d785059dex997.htm EX-99.7 EXHIBIT 99.7 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Perspective Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. Date: February 1, 2024 LANTHEUS HOLDINGS, INC. By: /s/ |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| January 23, 2024 |
EX-10.1 Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Lantheus Medical Imaging, Inc., a Delaware corporation (the “Company”), and Brian Markison (“Executive”), effective as of January 23, 2024 (the “Start Date”). In consideration of the premises and mutual covenants herein and for other good and valuable consideration |
|
| January 23, 2024 |
EX-99.1 Exhibit 99.1 Lantheus Announces CEO Succession Plan Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and Become Chair of the Board of Directors BEDFORD, Mass., January 23, 2024 – Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading ra |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2024 |
Exhibit 99.1 Lantheus Reports Preliminary Fiscal Year 2023 Revenue Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023 PYLARIFY revenue expected to be in the range of $851 - 853 million, pending final partner reconciliation, an increase of 61 - 62% over |
|
| November 2, 2023 |
Lantheus Reports Third Quarter 2023 Financial Results Exhibit 99.1 Lantheus Reports Third Quarter 2023 Financial Results •Worldwide revenue of $319.9 million for the third quarter 2023, representing an increase of 33.7% from the prior year period •GAAP net income of $132.0 million for the third quarter 2023, compared to GAAP net income of $61.2 million in the prior year period •GAAP fully diluted net income per share of $1.88 for the third quarter 20 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| August 3, 2023 |
Exhibit 99.2 Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readiness BEDFORD, Mass., August 3, 2023 – Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiothera |
|
| August 3, 2023 |
Exhibit 10.1 Certain identified information has been omitted from this exhibit because it is (i) not material and (ii) of the type that the registrant treats as private or confidential. [***] indicates the information has been omitted. FINAL OFFICE LEASE BY AND BETWEEN 201 BURLINGTON ROAD OWNER, LLC (AS LANDLORD) AND LANTHEUS MEDICAL IMAGING, INC. (AS TENANT) FOR PREMISES AT 201 BURLINGTON ROAD BE |
|
| August 3, 2023 |
Lantheus Reports Second Quarter 2023 Financial Results Exhibit 99.1 Lantheus Reports Second Quarter 2023 Financial Results •Worldwide revenue of $321.7 million for the second quarter 2023, representing an increase of 43.8% from the prior year period •GAAP net income of $94.1 million for the second quarter 2023, compared to GAAP net income of $43.1 million in the prior year period •GAAP fully diluted net income per share of $1.33 for the second quarter |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36 |
|
| May 31, 2023 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 (State or other jurisdiction of incorporation or organization) (Commission File Number) 201 Burlington Road, South Building Bedford, MA 01730 (Address of principal executive offices) (Zip C |
|
| May 31, 2023 |
Conflict Minerals Report for the reporting period January 1, 2022 through December 31, 2022. EX-1.01 Exhibit 1.01 Lantheus Holdings, Inc. Conflict Minerals Report For The Year Ended December 31, 2022 Lantheus Holdings, Inc. (together with its subsidiaries, the “Company” or “we”) is filing this Conflict Minerals Report for the 2022 calendar year (this “Report”) in accordance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Rule”). The R |
|
| May 16, 2023 |
As filed with the Securities and Exchange Commission on May 16, 2023 S-8 1 d472514ds8.htm S-8 As filed with the Securities and Exchange Commission on May 16, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S–8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lantheus Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 35-2318913 (State or other jurisdiction of incorporation or |
|
| May 16, 2023 |
EX-FILING FEES EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Lantheus Holdings, Inc. |
|
| May 4, 2023 |
Lantheus Reports First Quarter 2023 Financial Results Exhibit 99.1 Lantheus Reports First Quarter 2023 Financial Results •Worldwide revenue of $300.8 million for the first quarter 2023, representing an increase of 44.0% from the prior year period •GAAP net loss of $2.8 million for the first quarter 2023, compared to GAAP net income of $43.0 million in the prior year period •GAAP fully diluted net loss per share of $.04 for the first quarter 2023, com |
|
| May 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 4, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| May 1, 2023 |
Lantheus Holdings, Inc. 2023 Employee Stock Purchase Plan EX-10.1 Exhibit 10.1 LANTHEUS HOLDINGS, INC. 2023 Employee Stock Purchase Plan 1. Purpose. This Lantheus Holdings, Inc. 2023 Employee Stock Purchase Plan is intended to provide employees of the Company and its Participating Subsidiaries with an opportunity to acquire a proprietary interest in the Company through the purchase of shares of Common Stock. The Company intends that the Plan qualify as a |
|
| March 20, 2023 |
EX-99.1 Exhibit 99.1 201 Burlington Road Bedford, MA 01730 800.362.2668 www.lantheus.com Lantheus Announces Two Key Executive Promotions Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer BEDFORD, Mass., March 17, 2023 – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiother |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorpo |
|
| March 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| March 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| March 17, 2023 |
EX-99.1 Exhibit 99.1 201 Burlington Road Bedford, MA 01730 800.362.2668 www.lantheus.com Lantheus Announces Two Key Executive Promotions Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer BEDFORD, Mass., March 17, 2023 – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiother |
|
| February 23, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 23, 2023 |
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results •Worldwide revenue of $263.2 million and $935.1 million for the fourth quarter and full year 2022, representing increases of 103.1% and 119.9% over the prior year periods, respectively •GAAP net loss of $119.2 million and GAAP net income of $28.1 million for the fourth quarter and full year 2022, compared to GAAP net |
|
| February 23, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 |
|
| February 23, 2023 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Lantheus Holdings, Inc.’s (the “Company”, “us”, “we”, or “our”) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF CAPITAL STOCK T |
|
| February 23, 2023 |
Subsidiaries of Lantheus Holdings, Inc. Exhibit 21.1 LANTHEUS HOLDINGS, INC. SUBSIDIARIES Subsidiary State or Other Jurisdiction of Organization Lantheus Medical Imaging, Inc. Delaware Lantheus MI Canada, Inc. Canada Lantheus MI Real Estate, LLC Delaware Lantheus MI UK Limited England and Wales Lantheus EU Limited Ireland Lantheus Two, LLC Delaware Lantheus Three, LLC Delaware Progenics Pharmaceuticals, Inc. Delaware Molecular Insight P |
|
| February 9, 2023 |
LNTH / Lantheus Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01277-lantheusholdingsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Lantheus Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 516544103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to d |
|
| February 6, 2023 |
EX-99.1 Exhibit 99.1 201 Burlington Road Bedford, MA 01730 800.362.2668 www.lantheus.com Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease MK-6240 is an F18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease BEDFORD, Mass., Feb 6, 2023 – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| January 20, 2023 |
LNTH / Lantheus Holdings Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us5165441032012023.txt us5165441032012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) LANTHEUS HOLDINGS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 516544103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| January 11, 2023 |
41st Annual J.P. Morgan Healthcare Conference © 2023 Lantheus. All rights reserved. January 11, 2023 Exhibit 99.1 Safe Harbor Statements © 2023 Lantheus. All rights reserved. Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and |
|
| December 28, 2022 |
Amended and Restated Bylaws of Lantheus Holdings, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LANTHEUS HOLDINGS, INC. (a Delaware corporation) As of December 27, 2022 1 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Lantheus Holdings, Inc. (the ?Corporation?) for the election of directors and for the transaction of such other business as properly may come before such meeting shall be held at such pl |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| December 20, 2022 |
EX-99.1 Exhibit 99.1 Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma NORTH BILLERICA, MA, December 20, 2022 – Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions tha |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| December 8, 2022 |
EX-4.1 Exhibit 4.1 Execution Version LANTHEUS HOLDINGS, INC., as Issuer, LANTHEUS MEDICAL IMAGING, INC., as Guarantor AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 8, 2022 2.625% Convertible Senior Notes due 2027 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTIO |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| December 6, 2022 |
EX-99.1 Exhibit 99.1 Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027 NORTH BILLERICA, Mass., December 6, 2022 — Lantheus Holdings, Inc. (the “Company” or “Lantheus”) (NASDAQ: LNTH), today announced the pricing of $500 million in aggregate principal amount of the Company’s convertible senior notes due 2027 (the “Notes”). The Notes are being so |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| December 5, 2022 |
Exhibit 10.1 Published CUSIP Number: 51654LAM7 Revolving Loan CUSIP Number: 51654LAN5 Delayed Draw Term Loan CUSIP Number: 51654LAP0 CREDIT AGREEMENT Dated as of December 2, 2022 among LANTHEUS MEDICAL IMAGING, INC., as Borrower, LANTHEUS HOLDINGS, INC., The several Lenders from time to time parties hereto, CITIZENS BANK, N.A., as Administrative Agent and Collateral Agent, CITIZENS BANK, N.A., BAN |
|
| December 5, 2022 |
Exhibit 99.1 Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027 NORTH BILLERICA, Mass., December 5, 2022 ? Lantheus Holdings, Inc. (the ?Company? or ?Lantheus?) (NASDAQ: LNTH), today announced that it intends to offer, subject to market conditions and other factors, $500 million in aggregate principal amount of the Company?s convertible senior not |
|
| November 14, 2022 |
Exhibit 10.1 Certain identified information has been omitted from this exhibit because it is (i) not material and (ii) of the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EXECUTION VERSION LICENSE AND COLLABORATION AGREEMENT BETWEEN POINT BIOPHARMA, INC., LANTHEUS TWO, LLC AND, FOR PURPOSES OF SECTION 17.16 ONLY, LANTHEUS MEDICAL IM |
|
| November 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2022 |
Exhibit 10.2 Certain identified information has been omitted from this exhibit because it is (i) not material and (ii) of the type that the registrant treats as private or confidential. [***] indicates that information has been omitted. EXECUTION VERSION LICENSE AND COLLABORATION AGREEMENT BETWEEN POINT BIOPHARMA, INC., LANTHEUS THREE, LLC AND, FOR PURPOSES OF SECTION 17.16 ONLY, LANTHEUS MEDICAL |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| November 3, 2022 |
Lantheus Reports Third Quarter 2022 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Reports Third Quarter 2022 Financial Results ?Worldwide revenue of $239.3 million for the third quarter 2022, representing an increase of 134.4% from the prior year period ?GAAP net income of $61.2 million for the third quarter 2022, compared to GAAP net loss of $13.4 million in the prior year period |
|
| August 4, 2022 |
Lantheus Reports Second Quarter 2022 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Reports Second Quarter 2022 Financial Results ?Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year period ?GAAP net income of $43.1 million for the second quarter 2022, compared to GAAP net loss of $26.7 million in the prior year per |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36 |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| July 11, 2022 |
LNTH / Lantheus Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Lantheus Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 516544103 Date of Event Which Requires Filing of this Statement: June 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 15, 2022 |
Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations NORTH BILLERICA, MA, June 15, 2022?Lantheus Holdings, Inc. (?the Company?) (NASDAQ: LNTH), today announced two key management promotions. Paul Blanc |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 (State or other jurisdiction of incorporation or organization) (Commission File Number) 331 Treble Cove Road, North Billerica, MA 01862 (Address of principal executive offices) (Zip Code) Dani |
|
| May 31, 2022 |
Conflict Minerals Report for the reporting period January 1, 2021 through December 31, 2021. Exhibit 1.01 Lantheus Holdings, Inc. Conflict Minerals Report For The Year Ended December 31, 2021 Lantheus Holdings, Inc. (together with its subsidiaries, the “Company” or “we”) is filing this Conflict Minerals Report for the 2021 calendar year (this “Report”) in accordance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Rule”). The Rule impo |
|
| May 17, 2022 |
Welcome & Opening Remarks Mark Kinarney Senior Director, Investor Relations Lantheus 2022 Investor Day May 17 | New York City Exhibit 99.1 Welcome & Opening Remarks Mark Kinarney Senior Director, Investor Relations Safe Harbor and Non-GAAP Financial Measures Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to r |
|
| May 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2022 |
As filed with the Securities and Exchange Commission on May 12, 2022 As filed with the Securities and Exchange Commission on May 12, 2022 Registration No. |
|
| May 12, 2022 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Lantheus Holdings, Inc. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| May 2, 2022 |
Sixth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan Exhibit 10.1 Sixth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan This Amendment (this ?Amendment?) to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan, as in effect from time to time (the ?Plan?), is dated as of April 28, 2022. WHEREAS, pursuant to Section 16.2 of the Plan, the Compensation Committee desires to amend Section 4.1 of the Plan to increase the maximum number of |
|
| April 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2022 |
Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports First Quarter 2022 Financial Results ?Worldwide revenue of $208.9 million for the first quarter 2022, representing an increase of 125.8% from the prior year period ?GAAP net income of $43.0 million for the first quarter 2022, compared to GAAP net income of $9.0 million in the p |
|
| April 29, 2022 |
Exhibit 10.2 Lantheus Holdings, Inc. 2015 Equity Incentive Plan Restricted Stock Unit Award Agreement (Employee Time-Based Vesting) This Restricted Stock Unit Award Agreement (this ?Agreement?) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the ?Company?), and [?] (the ?Participant?), effective as of [?] (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| April 29, 2022 |
Form of Stock Option Award Agreement (Time Vesting) of Lantheus Holdings, Inc. Exhibit 10.4 Lantheus Holdings, Inc. 2015 Equity Incentive Plan Stock Option Award Agreement (Time Vesting) This Stock Option Award Agreement (this ?Agreement?) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the ?Company?), and [?] (the ?Participant?), effective as of [?] (the ?Date of Grant?). RECITALS WHEREAS, the Company has adopted the Lantheus Holdings, Inc. 2015 Equi |
|
| April 29, 2022 |
Exhibit 10.3 Lantheus Holdings, Inc. 2015 Equity Incentive Plan Restricted Stock Unit Award Agreement (Relative Total Shareholder Return Performance-Based Vesting) This Restricted Stock Unit Award Agreement including Exhibits A and B hereto (this ?Agreement?) is made by and between Lantheus Holdings, Inc., a Delaware corporation (the ?Company?), and [?] (the ?Participant?), effective as of [?] (th |
|
| April 29, 2022 |
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “****”, HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO LANTHEUS HOLDINGS, INC. |
|
| March 18, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| March 1, 2022 |
Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member NORTH BILLERICA, MA., March 1, 2022 - Lantheus Holdings, Inc. (?the Company?) (NASDAQ: LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| February 24, 2022 |
Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results ?Worldwide revenue of $129.6 million and $425.2 million for the fourth quarter and full year 2021, representing an increase of 37.6% and an increase of 25.3% over the prior year period, respectively ?GAAP net loss of $40.2 mil |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 |
|
| February 24, 2022 |
Subsidiaries of Lantheus Holdings, Inc. Exhibit 21.1 LANTHEUS HOLDINGS, INC. SUBSIDIARIES Subsidiary State or Other Jurisdiction of Organization Lantheus Medical Imaging, Inc. Delaware Lantheus MI Canada, Inc. Canada Lantheus MI Real Estate, LLC Delaware Lantheus MI UK Limited England and Wales Lantheus EU Limited Ireland Progenics Pharmaceuticals, Inc. Delaware Molecular Insight Pharmaceuticals, Inc. Delaware MNTX Royalties Sub LLC Del |
|
| February 24, 2022 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Lantheus Holdings, Inc.?s (the ?Company?, ?us?, ?we?, or ?our?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF CAPITAL STOCK T |
|
| February 15, 2022 |
Exhibit A Exhibit A AGREEMENT The undersigned agree that this Amendment No. 2 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.01 per share, of Lantheus Holdings, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 15, 2022 |
LNTH / Lantheus Holdings Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
LNTH / Lantheus Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Lantheus Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 516544103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 4, 2022 |
LNTH / Lantheus Holdings Inc / WELLINGTON TRUST Co N A - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Lantheus Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 516544103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| December 27, 2021 |
Amended and Restated Bylaws of Lantheus Holdings, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF LANTHEUS HOLDINGS, INC. (a Delaware corporation) Effective April 26, 2018 As of December 27, 2021 ARTICLE I STOCKHOLDERS Section 1.01. Annual Meetings. The annual meeting of the stockholders of Lantheus Holdings, Inc. (the ?Corporation?) for the election of directors and for the transaction of such other business as properly may come before such meeting s |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| December 10, 2021 |
LNTH / Lantheus Holdings Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Lantheus Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 516544103 (CUSIP Number) November 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commiss |
|
| November 4, 2021 |
Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Third Quarter 2021 Financial Results ?Worldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year period ? GAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP net loss of $6.4 million in the prior |
|
| October 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| August 4, 2021 |
As filed with the Securities and Exchange Commission on August 4, 2021 As filed with the Securities and Exchange Commission on August 4, 2021 Registration No. |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36 |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| July 28, 2021 |
Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results ?Worldwide revenue of $101.1 million for the second quarter 2021, representing an increase of 53.1% from the prior year period ? GAAP net loss of $26.7 million for the second quarter 2021, compared to GAAP net loss of $7.0 million in the pr |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| May 28, 2021 |
Conflict Minerals Report for the reporting period January 1, 2020 through December 31, 2020. Exhibit 1.01 Lantheus Holdings, Inc. Conflict Minerals Report For The Year Ended December 31, 2020 Lantheus Holdings, Inc. (together with its subsidiaries, the ?Company? or ?we?) is filing this Conflict Minerals Report for the 2020 calendar year (this ?Report?) in accordance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the ?Rule?). Rule 13p-1 im |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 331 Treble Cove Road, North Billerica, MA 01862 (Address of |
|
| May 27, 2021 |
Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Receives U.S. FDA Approval of PYLARIFY? (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer PYLARIFY will be available immediately to imaging centers in parts of the mid-Atlantic and southern regions and is expected to be broadly availa |
|
| May 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 4, 2021 |
Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results ?Worldwide revenue of $92.5 million for the first quarter 2021, representing an increase of 2.0% from the prior year period ? Net income of $9.0 million for the first quarter 2021, compared to net income of $3.3 million in the prior year per |
|
| May 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 4, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| April 29, 2021 |
Fifth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan. Exhibit 10.1 Fifth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan This Amendment (this ?Amendment?) to the Lantheus Holdings, Inc. 2015 Equity Incentive Plan, as in effect from time to time (the ?Plan?), is dated as of April 28, 2021. WHEREAS, pursuant to Section 16.2 of the Plan, the Compensation Committee desires to amend Section 4.1 of the Plan to increase the maximum number of |
|
| April 1, 2021 |
Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel Names Daniel Niedzwiecki as Senior Vice President and General Counsel NORTH BILLERICA, MA, April 1, 2021 - Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of inno |
|
| April 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission |
|
| April 1, 2021 |
Exhibit 10.1 Execution Version CONSULTING AGREEMENT This Consulting Agreement is made by and between Lantheus Medical Imaging, Inc. (the ?Company?) and Michael P. Duffy (?you?) (each of the Company and you, individually, a ?Party? and, collectively, the ?Parties?), as of March 31, 2021 (the ?Effective Date?) (this ?Agreement?). Each of the Parties, intending to be legally bound, agree as follows: |
|
| March 18, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 |
|
| February 25, 2021 |
Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results ?Worldwide revenue of $94.2 million and $339.4 million for the fourth quarter and full year 2020, representing an increase of 5.4% and a decline of 2.3% over the prior year period, respectively ?Net loss of $3.4 million and $13.5 million for |
|
| February 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| February 25, 2021 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description sets forth certain material terms and provisions of Lantheus Holdings, Inc.?s (the ?Company?, ?us?, ?we?, or ?our?) securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. DESCRIPTION OF CAPITAL STOCK T |
|
| February 25, 2021 |
Subsidiaries of Lantheus Holdings, Inc. Exhibit 21.1 LANTHEUS HOLDINGS, INC. SUBSIDIARIES Subsidiary State or Other Jurisdiction of Organization Lantheus Medical Imaging, Inc. Delaware Lantheus MI Canada, Inc. Ontario, Canada Lantheus MI Real Estate, LLC Delaware Lantheus MI Radiopharmaceuticals, Inc. Commonwealth of Puerto Rico Lantheus MI UK Limited England and Wales Lantheus EU Limited Ireland Progenics Pharmaceuticals, Inc. Delaware |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Lantheus Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 516544103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Lantheus Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 516544103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Lantheus Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 516544103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2021 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| December 9, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| December 9, 2020 |
EX-99.1 Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent PDUFA action date of May 28, 2021 assigned by U.S. Food and Drug Administration NORTH BILLERICA, MA., December 9, 2020 - Lantheus Holdings, Inc. |
|
| December 3, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| December 3, 2020 |
EX-99.1 Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement Transaction Extends Relationship with Strategic Partner NORTH BILLERICA, MA., December 3, 2020 - Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Compan |
|
| November 18, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| November 18, 2020 |
EX-99.1 Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature Commercially Available in Early 2021 NORTH BILLERICA, MA., November 18, 2020 - Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissio |
|
| November 5, 2020 |
Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Third Quarter 2020 Financial Results •Worldwide revenue of $88.5 million for the third quarter 2020, representing an increase of 3.2% from the prior year period •Net loss of $6.4 million for the third quarter 2020, compared to net income of $4.9 million in the prior year period |
|
| November 5, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| October 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commiss |
|
| September 30, 2020 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commiss |
|
| September 30, 2020 |
EX-99.1 Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings Submits New Drug Application to the U.S. FDA for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent NORTH BILLERICA, MA., September 30, 2020 - Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pha |
|
| July 31, 2020 |
lantheus-amendmentno1toc Execution Version AMENDMENT NO. 1 TO CREDIT AGREEMENT This AMENDMENT NO. 1 TO CREDIT AGREEMENT (this “Amendment”), dated as of June 19, 2020, among LANTHEUS MEDICAL IMAGING, INC., a Delaware corporation (the “Borrower”), LANTHEUS HOLDINGS, INC., a Delaware corporation (“Holdings”), each other Guarantor party hereto and WELLS FARGO BANK, N.A., as administrative agent and co |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36 |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commission F |
|
| July 30, 2020 |
Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results Exhibit 99.1 331 Treble Cove Road North Billerica, MA 01862 800.362.2668 www.lantheus.com Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results •Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline •Worldwide revenue of $66.0 million for the second quarter 2020, representing a decrease of 23.0% from t |
|
| June 26, 2020 |
EX-4.5 Exhibit 4.5 LANTHEUS HOLDINGS, INC. 2018 PERFORMANCE INCENTIVE PLAN (F/K/A PROGENICSPHARMACEUTICALS, INC.2018 PERFORMANCE INCENTIVE PLAN) (As amended, effective June 19, 2020) 1. PURPOSE OF PLAN The purpose of this Lantheus Holdings, Inc. 2018 Performance Incentive Plan (formerly known as Progenics Pharmaceuticals, Inc. 2018 Performance Incentive Plan) (this “Plan”) of Lantheus Holdings, In |
|
| June 26, 2020 |
EX-4.4 Exhibit 4.4 LANTHEUS HOLDINGS, INC. 2005 STOCK INCENTIVE PLAN (F/K/A PROGENICS PHARMACEUTICALS, INC. 2005 STOCK INCENTIVE PLAN) (As amended, effective June 19, 2020) 1. PURPOSE The purpose of the Lantheus Holdings, Inc. 2005 Stock Incentive Plan (formerly known as the Progenics Pharmaceuticals, Inc. 2005 Stock Incentive Plan) is to further align the interests of employees, officers, non-emp |
|
| June 26, 2020 |
S-8 As filed with the Securities and Exchange Commission on June 26, 2020 Registration No. |
|
| June 23, 2020 |
PGNX / Progenics Pharmaceuticals, Inc. / Lantheus Holdings, Inc. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Progenics Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0013 per share (Title of Class of Securities) 743187106 (CUSIP Number) Michael P. Duffy Lantheus Holdings, Inc. 331 Treble Cove Road North Billerica, Massachusetts 01862 |
|
| June 22, 2020 |
Lantheus Completes Merger with Progenics EX-99.1 Exhibit 99.1 Lantheus Completes Merger with Progenics NORTH BILLERICA, Mass. and NEW YORK-(BUSINESS WIRE)—June 22, 2020— Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has c |
|
| June 22, 2020 |
Entry into a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 333-196998 35-2318913 (State or other jurisdiction of incorporation) (Commiss |
|
| June 22, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| June 22, 2020 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION Contingent Value Rights Agreement between Lantheus Holdings, Inc. and Computershare Inc. Computershare Trust Company, N.A. collectively, as Rights Agent Dated as of June 19, 2020 Table of Contents Page ARTICLE I DEFINITIONS; INTERPRETATION 1 Section 1.01 Definitions 1 Section 1.02 Interpretation 3 ARTICLE II CONTINGENT VALUE RIGHTS 6 Section 2.01 Holders of C |
|
| June 16, 2020 |
Lantheus Stockholders Approve Share Issuance For Merger with Progenics EX-99.1 Exhibit 99.1 Lantheus Stockholders Approve Share Issuance For Merger with Progenics NORTH BILLERICA, MA - June 16, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents announced that at a special meeting hel |
|
| June 16, 2020 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2020 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation) (Commissi |
|
| May 29, 2020 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36569 35-2318913 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 331 Treble Cove Road, North Billerica, MA 01862 (Address |
|
| May 29, 2020 |
Conflict Minerals Report for the reporting period January 1, 2019 through December 31, 2019. EX-1.01 Exhibit 1.01 Lantheus Holdings, Inc. Conflict Minerals Report For The Year Ended December 31, 2019 Lantheus Holdings, Inc. (together with its subsidiaries, the “Company” or “we”) is filing this Conflict Minerals Report for the 2019 calendar year (this “Report”) in accordance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the “Rule”). Rule |
|
| May 26, 2020 |
LNTH / Lantheus Holdings, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 14, 2020 |
JOINT PROXY STATEMENT/PROSPECTUS SUPPLEMENT MAY 14, 2020 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-234627 JOINT PROXY STATEMENT/PROSPECTUS SUPPLEMENT MAY 14, 2020 This is a supplement (this “supplement”) to the joint proxy statement/prospectus of Lantheus Holdings, Inc. (“Lantheus Holdings”) and Progenics Pharmaceuticals, Inc. (“Progenics”), dated March 19, 2020, that was mailed to stockholders of record as of the close of business on |
